SCHEMBL22290239

SCHEMBL22290239

NCc1ncccc1-c1ccccn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.48
LMNA P02545 3/20 0.48
CCR1 P32246 2/20 0.48
CCR5 P51681 2/20 0.48
CCR8 P51685 2/20 0.48
CYP1A2 P05177 1/20 0.48
POLB P06746 1/20 0.48
METAP1 P53582 1/20 0.48
BLM P54132 1/20 0.48
HIF1A Q16665 1/20 0.48
DOHH Q9BU89 1/20 0.48
P4HTM Q9NXG6 1/20 0.48
TDO2 P48775 1/20 0.43
NPC1 O15118 6/20 0.42
RAB9A P51151 5/20 0.42
TP53 P04637 4/20 0.42
ALOX15 P16050 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
TDP1 Q9NUW8 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22333781 0.81 KDM4E (0.48) KDM4ELMNACCR1CCR5CCR8
SCHEMBL3790206 0.78 KDM4E (0.50) KDM4ELMNACCR1CCR5CCR8
SCHEMBL29496884 0.78 KDM4E (0.50) KDM4ELMNACCR1CCR5CCR8
SCHEMBL2181299 0.78 DPP4 (0.50) KDM4ETDO2RAB9ATP53L3MBTL1
SCHEMBL22290175 0.77 KDM4E (0.48) KDM4ELMNACCR1CCR5CCR8
SCHEMBL858806 0.76 KDM4E (0.72) KDM4ELMNACCR1CCR5CCR8
Ethylene SCHEMBL27759749 0.76 DPP4 (0.47) KDM4ELMNACCR1CCR5CCR8
SCHEMBL22881677 0.74 KDM4E (0.68) KDM4ELMNACCR1CCR5CCR8
SCHEMBL12853986 0.74 KDM4E (0.68) KDM4ELMNACCR1CCR5CCR8
SCHEMBL12853975 0.74 KDM4E (0.68) KDM4ELMNACCR1CCR5CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210387968-A1 HETEROARYLMETHYLENE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES INC (US) 2021-12-16 US disclosed
EP-3917919-A1 HETEROARYLMETHYLENE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS Ideaya Biosciences, Inc. (US) 2021-12-08 EP disclosed
WO-2020160213-A1 HETEROARYLMETHYLENE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-08-06 WO disclosed
WO-2020160213-A1 HETEROARYLMETHYLENE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210387968-A1 HETEROARYLMETHYLENE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS POLQ, POLH, POLB KDM4E 3701/4885LMNA 2425/4885CCR1 3972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.